Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Xalkori, crizotinib (PF-02341066)
Also known as: PF-2341066
print preview
bookmark
share with colleague
General Information
Company
Pfizer Inc.
Description
Dual inhibitor of c-Met receptor tyrosine kinase and anaplastic lymphoma kinase (ALK) and their oncogenic variants
Molecular Target
c-Met receptor tyrosine kinase
;
Anaplastic lymphoma kinase (ALK)
Mechanism of Action
Anaplastic lymphoma kinase (Ki-1) (ALK) inhibitor; c-Met receptor tyrosine kinase inhibitor
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Disease Category
Standard Indication
Indication Details
Partners
Milestones
Latest Stage of Development
More
Archive Items are loading
Set Email Alert
dummy